Home LiteratureArticle Details
PMID: 2139697 Published · ppublish English Journal Article

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.

The Journal of experimental medicine ·Vol. 171 ·No. 5 ·1990-05-01 ·Pages 1527-33

Nagler A, Lanier LL, Phillips JH

Abstract

The majority of human NK cells express low affinity IgG Fc receptors (CD16+), whereas a minor subset of NK cells lack Fc receptor expression (CD16-). In contrast to CD16+ NK cells that express only p75 IL-2 receptors, CD16- NK cells constitutively co-express both p75 and p55 IL-2 receptors in vivo and preferentially respond to low concentrations of IL-2 with increased cytolytic activation and proliferation. Scatchard analysis demonstrated the presence of approximately 1,200 high affinity (approximately 25 pM kD) and approximately 9,600 intermediate affinity (approximately 2 nM kD) IL-2 receptors on CD16- NK cells. CD16+ NK cells expressed only a single intermediate affinity IL-2 receptor of approximately 1.9 nM kD (approximately 9,000 sites per cell). The IL-2 binding data thus substantiated the phenotypic and functional studies and definitively show that the differential responsiveness of CD16- and CD16+ NK cells to IL-2 is manifested through different affinity IL-2 receptors.

MeSH Terms
Antigens, CD/analysis Antigens, Differentiation/analysis Cells, Cultured Cytotoxicity, Immunologic Flow Cytometry Fluorescent Antibody Technique Humans Immunoglobulin G Interleukin-2/metabolism Killer Cells, Natural/immunology Kinetics Receptors, Fc/analysis Receptors, IgG Receptors, Interleukin-2/biosynthesis,metabolism
Chemicals
Antigens, CD Antigens, Differentiation Immunoglobulin G Interleukin-2 Receptors, Fc Receptors, IgG Receptors, Interleukin-2
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Nagler A
Becton Dickinson Monoclonal Center, Inc., San Jose, California 95131.
Lanier L L
Phillips J H
References (16)
16 references, click to expand
  1. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    J Clin Oncol. 1987 Dec;5(12):1933-41 PMID: 3500280
  2. The interleukin 2 receptor. Functional consequences of its bimolecular structure.
    J Exp Med. 1987 Oct 1;166(4):1055-69 PMID: 3116143
  3. Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.
    Proc Natl Acad Sci U S A. 1989 Mar;86(6):1982-6 PMID: 2467293
  4. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
    J Immunol. 1989 Apr 15;142(8):2949-54 PMID: 2467946
  5. Activation of natural killer cells via the p75 interleukin 2 receptor.
    J Exp Med. 1989 Jul 1;170(1):291-6 PMID: 2787381
  6. Comparative studies of human FcRIII-positive and negative natural killer cells.
    J Immunol. 1989 Nov 15;143(10):3183-91 PMID: 2530273
  7. Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells.
    Clin Immunol Immunopathol. 1990 Jan;54(1):126-33 PMID: 2403487
  8. Response of resting human peripheral blood natural killer cells to interleukin 2.
    J Exp Med. 1984 Oct 1;160(4):1147-69 PMID: 6434688
  9. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    J Immunol. 1985 Feb;134(2):794-801 PMID: 3871216
  10. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
    J Immunol. 1986 Jun 15;136(12):4480-6 PMID: 3086432
  11. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
    J Exp Med. 1986 Sep 1;164(3):814-25 PMID: 3489062
  12. Natural killer cells: definition of a cell type rather than a function.
    J Immunol. 1986 Nov 1;137(9):2735-9 PMID: 3489775
  13. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.
    J Exp Med. 1987 Jan 1;165(1):223-38 PMID: 3098894
  14. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9694-8 PMID: 3099289
  15. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.
    Nature. 1987 Jun 11-17;327(6122):518-22 PMID: 3108674
  16. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor.
    J Exp Med. 1989 Apr 1;169(4):1323-32 PMID: 2784485
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1990-05-01
Pages
1527-33
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2187903
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]